Phase II Study of Range and Schedule of rPA Doses
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00170456 |
Recruitment Status
:
Completed
First Posted
: September 15, 2005
Last Update Posted
: September 15, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prevention of Bacillus Anthracis (Anthrax) Infection | Biological: rPA vaccine containing alhydrogel | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 415 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Prevention |
Official Title: | A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects |
Study Start Date : | March 2005 |
Actual Primary Completion Date : | January 2007 |
Actual Study Completion Date : | February 2007 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
Low dose rPA vaccine regime 1
|
Biological: rPA vaccine containing alhydrogel |
Active Comparator: 2
Low dose rPA vaccine regime 2
|
Biological: rPA vaccine containing alhydrogel |
Active Comparator: 3
High dose rPA vaccine regime 1
|
Biological: rPA vaccine containing alhydrogel |
Active Comparator: 4
High dose rPA vaccine regime 2
|
Biological: rPA vaccine containing alhydrogel |
- Safety of rPA vaccine
- Immunogenicity of rPA vaccine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy males or females.
- Aged between 18-55 years (inclusive).
- A body mass index (BMI) of 18-35.
- Signed informed consent, which includes information about the potential risks and effects of rPA.
- A medical history without major organ pathology (e.g. cardiac, immunological, psychiatric, endocrine or neurological disorders, cancer or other wasting diseases - (adequately treated actinic keratosis, or basal cell carcinoma [BCC], or carcinoma in situ [CIS] of the cervix are permitted).
-
A female may be enrolled if one of the following criteria applies:
Either If of child-bearing capacity then: A female is not pregnant or breast feeding AND is routinely using adequate injectable or transdermal (administered at the recommended frequency) or oral contraception (at a stable dose for at least three months prior to the first dose of vaccine) and will continue to do so during the study, augmenting this contraceptive measure with a barrier method OR is sexually abstinent OR is monogamous and has a partner who has had a vasectomy (>1 month previously) OR is using a commonly recognised copper and hormone implanted intrauterine device (IUD) such as TCu-380A, TCu-220C, MLCu-375, Nova-T or LNG-20. In addition, the subject must have a negative blood pregnancy test prior to enrolment into the study and negative urine pregnancy test pre-dose.
Or A female is post menopausal (defined as a female with no menstrual cycle for at least 24 months and of menopausal age (>45 years).
Or A female with no menstrual cycle for between 12 and 24 months and of menopausal age (>45 years) who has a negative blood pregnancy test prior to enrolment into the study and a negative urine pregnancy test pre-dose.
Or A female has been surgically sterilised (confirmed by review of medical record).
Or A female has had a total hysterectomy at least 3 months prior to the start of the study (confirmed by review of medical record).
- A male may be enrolled if willing to use barrier methods of contraception and whose partner is using an acceptable form of contraception for 3 months post each dose.
- Able to understand the informed consent form and other documents required to be read by the subject.
Exclusion Criteria:
- Presence of any clinically significant medical condition as determined by the Investigator.
- Medically significant hypersensitivity or idiosyncratic reaction related to any medical product including vaccines.
- History or evidence of drug abuse.
- Participation in a clinical study of an investigational vaccine within 3 months prior to the start of the study or an investigational drug product within 30 days prior to the start of the study.
- Use of any prescription or non-prescription medication within 7 days prior to the first dosing with the exception of over-the-counter (OTC) antihistamine, non-steroidal anti-inflammatory drugs (NSAID), acetaminophen, OTC decongestants or oral/injectable/transdermal contraceptives. Any medication taken within 7 days of the first dosing will be recorded.
- History or suspicion of inability to co-operate adequately.
- Donation of blood or blood products for a period of 4 weeks prior to participation in the study.
- Immunodeficiency or clinically active autoimmune disease.
- Positive urine alcohol and drug screen for drugs of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids, and barbiturates).
- Positive test for human immunodeficiency virus (HIV), and/or hepatitis B and/or hepatitis C.
- Vaccination(s) with a live vaccine in the previous 4 weeks or killed / inactivated vaccines in the previous 3 weeks.
- Blood or plasma transfusions, or pooled gamma-globulin in the previous 3 months and need for blood or plasma transfusions during this study.
- Received anthrax vaccine or anthrax immune globulin or been otherwise exposed to B. anthracis.
- Clinically relevant abnormal findings on routine physical examination.
- Clinically significant out-of-range laboratory tests at screening including: urinalysis, serum creatinine, lactate dehydrogenase (LDH), potassium, glucose, liver function tests (LFT); absolute neutrophil count, platelet count, white blood cell count, electrolytes, clotting and blood haemoglobin.
- Twelve-lead ECG recording with clinically relevant signs of pathology and conduction disturbances as judged by the investigator.
- Presence of tattoos that cover or partially cover the upper arm.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00170456
United Kingdom | |
GDRU, Quintiles Ltd | |
London, United Kingdom | |
Simbec Research Limited | |
Merthyr Tydfil, United Kingdom, CF48 4DR |
Principal Investigator: | Timothy Mant, MD | GDRU, London, UK |
ClinicalTrials.gov Identifier: | NCT00170456 History of Changes |
Other Study ID Numbers: |
05-0003 QGUY/2004/AV-rPA/-01 |
First Posted: | September 15, 2005 Key Record Dates |
Last Update Posted: | September 15, 2008 |
Last Verified: | September 2008 |
Keywords provided by PharmAthene UK Limited:
Anthrax vaccine |
Additional relevant MeSH terms:
Anthrax Bacillaceae Infections Gram-Positive Bacterial Infections Bacterial Infections Vaccines Aluminum Hydroxide |
Immunologic Factors Physiological Effects of Drugs Adjuvants, Immunologic Antacids Molecular Mechanisms of Pharmacological Action Gastrointestinal Agents |